EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment

Simon Birk Kjær Jensen, Victor Sørensen, Rasmus Michael Sandsdal, Eva Winning Lehmann, Julie Rehné Lundgren, Christian Rimer Juhl, Charlotte Janus, Tummas Ternhamar, Bente Merete Stallknecht, Jens Juul Holst, Niklas Rye Jørgensen, Jens-Erik Beck Jensen und 2 weitere

JAMA Network Open · 25.06.2024 · 7 (6) · e2416775

DOI: 10.1001/jamanetworkopen.2024.16775 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 25.06.2024. Verfasst von Simon Birk Kjær Jensen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Liraglutide, Bone Density, Exercise, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 167-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance A major concern with weight loss is concomitant bone loss. Exercise and glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent weight loss strategies that may protect bone mass despite weight loss.

Objective

To investigate bone health at clinically relevant sites (hip, spine, and forearm) after diet-induced weight loss followed by a 1-year intervention with exercise, liraglutide, or both combined. Design, Setting, and Participants This study was a predefined secondary analysis of a randomized clinical trial conducted between August 2016 and November 2019 at the University of Copenhagen and Hvidovre Hospital in Denmark. Eligible participants included adults aged 18 to 65 years with obesity (body mass index of 32-43) and without diabetes. Data analysis was conducted from March to April 2023, with additional analysis in February 2024 during revision.

Interventions

After an 8-week low-calorie diet (800 kcal/day), participants were randomized to 1 of 4 groups for 52 weeks: a moderate- to vigorous-intensity exercise program (exercise alone), 3.0 mg daily of the GLP-1 RA liraglutide (liraglutide alone), the combination, or placebo. Main Outcomes and Measures The primary outcome was change in site-specific bone mineral density (BMD) at the hip, lumbar spine, and distal forearm from before the low-calorie diet to the end of treatment, measured by dual-energy x-ray absorptiometry in the intention-to-treat population.

Results

In total, 195 participants (mean [SD] age, 42.84 [11.87] years; 124 female [64%] and 71 male [36%]; mean [SD] BMI, 37.00 [2.92]) were randomized, with 48 participants in the exercise group, 49 participants in the liraglutide group, 49 participants in the combination group, and 49 participants in the placebo group. The total estimated mean change in weight losses during the study was 7.03 kg (95% CI, 4.25-9.80 kg) in the placebo group, 11.19 kg (95% CI, 8.40-13.99 kg) in the exercise group, 13.74 kg (95% CI, 11.04-16.44 kg) in the liraglutide group, and 16.88 kg (95% CI, 14.23-19.54 kg) in the combination group. In the combination group, BMD was unchanged compared with the placebo group at the hip (mean change, −0.006 g/cm 2 ; 95% CI, −0.017 to 0.004 g/cm 2 ; P = .24) and lumbar spine (−0.010 g/cm 2 ; 95% CI, −0.025 to 0.005 g/cm 2 ; P = .20). Compared with the exercise group, BMD decreased for the liraglutide group at the hip (mean change, −0.013 g/cm 2 ; 95% CI, −0.024 to −0.001 g/cm 2 ; P = .03) and spine (mean change, −0.016 g/cm 2 ; 95% CI, −0.032 to −0.001 g/cm 2 ; P = .04). Conclusions and Relevance In this randomized clinical trial, the combination of exercise and GLP-1RA (liraglutide) was the most effective weight loss strategy while preserving bone health. Liraglutide treatment alone reduced BMD at clinically relevant sites more than exercise alone despite similar weight loss. Trial Registration EudraCT: 2015-005585-32

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutideBone DensityExerciseGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMaleMiddle AgedAdultObesityWeight LossHypoglycemic AgentsAgedCombined Modality TherapyDenmark

Substanzen

LiraglutideHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.
  • Department of Endocrinology, Hvidovre University Hospital, Copenhagen, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Zitieren

APA

Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., Jørgensen, N. R., Jensen, J. B., Madsbad, S., & Torekov, S. S. (2024). Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment. JAMA Network Open, 7(6), e2416775. https://doi.org/10.1001/jamanetworkopen.2024.16775

Vancouver

Jensen SBK, Sørensen V, Sandsdal RM, Lehmann EW, Lundgren JR, Juhl CR, et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment. JAMA Network Open. 2024;7(6):e2416775. doi:10.1001/jamanetworkopen.2024.16775

BibTeX
@article{Jensen2024,
  author = {Jensen, Simon Birk Kjær and Sørensen, Victor and Sandsdal, Rasmus Michael and Lehmann, Eva Winning and Lundgren, Julie Rehné and Juhl, Christian Rimer and Janus, Charlotte and Ternhamar, Tummas and Stallknecht, Bente Merete and Holst, Jens Juul and Jørgensen, Niklas Rye and Jensen, Jens-Erik Beck and Madsbad, Sten and Torekov, Signe Sørensen},
  title = {Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {6},
  pages = {e2416775},
  doi = {10.1001/jamanetworkopen.2024.16775}
}
Kostenlos starten →